Updated May 2026
Rybelsus vs Zepbound
Side-by-side comparison of Rybelsus (semaglutide (oral)) and Zepbound (tirzepatide (injection)) across efficacy, food restrictions, monthly cost, and Medicare Bridge coverage.
Our pick for most patients
Zepbound
Based on the data below, Zepbound wins on covered under the Medicare GLP-1 Bridge ($50/mo from Jul 1, 2026). Your situation may differ — try the personalized matcher on the homepage or compute your real out-of-pocket with the cost calculator on each medication's detail page.
| Field | Rybelsus | Zepbound |
|---|---|---|
| Route | tablet · daily | injection · weekly |
| Avg weight loss | 8–10% | 18–22% |
| Food restriction | 30-min fast required | No food restriction |
| Cash from | $998/mo | $299/mo |
| Savings card | — | — |
| Medicare Bridge | Tier 4 | $50/mo ✓ |
| A1c reduction | −1.4% | — |
| FDA approved | 2019-09 | 2023-11 |
- RouteRybelsustablet · dailyZepboundinjection · weekly
- Avg weight lossRybelsus8–10%Zepbound18–22%
- Food restrictionRybelsus30-min fast requiredZepboundNo food restriction
- Cash fromRybelsus$998/moZepbound$299/mo
- Savings cardRybelsus—Zepbound—
- Medicare BridgeRybelsusTier 4Zepbound$50/mo ✓
- A1c reductionRybelsus−1.4%Zepbound—
- FDA approvedRybelsus2019-09Zepbound2023-11
Pick Rybelsus if…
- You're needle-averse
Pick Zepbound if…
- You can't reliably do a fasting window before meds
- You're on Medicare and want the $50/mo Bridge price
- Cash pay matters more than peak weight loss ($299/mo cheaper)
- You want the higher peak efficacy (22% vs 10%)
Not sure which fits?
The 30-second matcher on the homepage scores every 2026 GLP-1 against your goals + preferences and recommends the best fit.